NCT07166003

Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer

Effects of Neoadjuvant Immunotherapy on Patients With Lung Cancer: a Prospective, Observational Study

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years – 79 Years
• Healthy volunteers: —

Summary

The goal of this observational study is to learn about the long-term effects of neoadjuvant immunotherapy in patients with lung cancer. The main questions it aims to answer are: * Does pneumonectomy bring more benefits for pateints than lobectomy? * Does surgery bring more benefits for patients than non-surgery modalities (such as radiotherapy) after neoadjuvnat immunotherapy? Participants will receive neoadjuvant treatment and the study will analyze the data.

Detailed description

This observational study aims to comprehensively evaluate the effectiveness and long-term clinical outcomes of neoadjuvant treatment in patients with lung cancer. Central to this investigation are two key questions: ·Does pneumonectomy bring more benefits for pateints than lobectomy? * Does surgery bring more benefits for patients than non-surgery modalities (such as radiotherapy) after neoadjuvnat immunotherapy? Participants will receive neoadjuvant treatment, and through rigorous analysis of data, this study endeavors to provide nuanced insights into these fundamental queries, fostering advancements in clinical decision-making and patient management strategies.

Conditions

• Lung Cancer, Non-Small Cell
• Immunotherapy

Interventions

Type	Name	Description
PROCEDURE	Pneumonectomy	Patients will receive pneumonectomy after neoadjuvant treatment
PROCEDURE	lobectomy	Patients will receive lobectomy after neoadjuvant immunotherapy.
RADIATION	radiotherapy	Patients will receive radiotherapy after neoadjuvant immunotherapy.
DRUG	Anti-Tumor Drugs	Patients will receive anti-tumor drugs.

Timeline

• Start date: 2025-04-20
• Primary completion: 2027-02-02
• Completion: 2030-04-14
• First posted: 2025-09-10
• Last updated: 2025-09-10

Locations

1 site across 1 country: China